Sentences with phrase «drug price hikes»

Another drug maker says it will voluntarily limit drug price hikes.

And after announcing a «social contract» to keep drug price hikes below 10 percent a year, his company raised a slew of prices by 9.5 percent.

Rising insurance premiums, surprise medical bills, unfair drug price hikes — if you read the headlines, our collective anxiety over health costs is well - founded.

Persistent media and political focus on drug price hikes and Congressional inquiries into distribution models hasn't helped, either.

With recent uproar over drug price hikes by Valeant (vrx), Mylan (myl) and Martin Shkreli, healthcare experts have reached a consensus: The system as we know it is officially broken.

Sanofi on Tuesday pledged to limit drug price hikes in the U.S. to a level below medical inflation.

Infamous for his own drug price hikes at former firm Turing Pharmaceuticals and current indictment on securities fraud charges, Shkreli began a defense of Mylan during a Tuesday interview with CBS News.

While exorbitant drug price hikes by Martin Shkreli's Turing Pharmaceuticals and Valeant have sparked outrage in Washington and tanked the stock prices of much of the pharmaceutical sector in the last six months, there's growing evidence that the controversy may be more smoke than fire.

He's also been leading an effort to convince drug makers to voluntarily back away from massive drug price hikes, promoting a «social contract» with patients and warning that lawmakers will take matters into their own hands if the practice proceeds unabated.

And without Philidor, she said, Valeant could face a big hole in its revenue generation that can't be filled immediately by quick acquisition or further drug price hikes.

Activist hedge fund investor and recent Valeant Pharmaceuticals (vrx) board appointee Bill Ackman on Wednesday slammed the company's steep drug price hikes in testimony before the U.S. Senate Special Committee on Aging, going so far as to say the cost bumps «contributed to healthcare inflation and called into question the company's commitment to the patients it serves.»

He added that the media focuses on examples of individual drug price hikes, it has overlooked the fact that expense of drugs as a proportion of healthcare spending has remained «remarkably constant» over the years.

On the heels of rival diabetes drug maker Novo Nordisk's announcement that it will limit branded drug price hikes to the single digits going forward, U.S. pharma giant Eli Lilly announced Tuesday that it is partnering with benefits manager Express Scripts and a mobile health platform hosted by Blink Health to slash patients» insulin costs.

The politics of Marathan Pharma's Duchenne drug price hike are getting messy.

(None of the charges mention anything about Shkreli's infamous drug price hikes at his new company Turing.)

But her underlying point isn't totally invalid — the furor over drug price hikes like Mylan's is forcing legislators and private companies alike to finally confront the issue head - on, and highlighting just how difficult the disparate and largely opaque American medical financing system makes it to address these problems in a serious way.

Don't blame us for dramatic drug price hikes — that was the clear message from drugstore and pharmacy benefits manager CVS Health on Thursday.

If you're «Pharma Bro» Martin Shkreli, the often - reviled poster boy for prescription drug price hikes, you turn to social media, of course.

Investors challenge pay packages at pharma companies, saying they incentivize drug price hikes.

Trump reportedly pressed the biopharma chiefs on drug price hikes, which he's heavily criticized as the sector «getting away with murder,» and pushed for more U.S. - based production and manufacturing of drugs.

Big pharma has been a persistent villain in the public's consciousness over the past year in the wake of exorbitant drug price hikes, including on ancient medications.

There's been a recent trend in biopharma where some companies, led by Allergan (agn) CEO Brent Saunders» new «social contract» with patients, are voluntarily pledging to limit drug price hikes and being more transparent about which products have seen price increases.

Strikingly, for all the media attention on the case (propagated by Shkreli's troll - y Twitter antics and relish for stirring the pot), the trial verdict had nothing to do with the drug price hike that thrust him into the national limelight.

Hillary Clinton has been considered one of the biggest threats to biotech investors ever since September 2015, when she pushed biotech stocks into a bear market with a single tweet about cracking down on drug price hikes that cost the sector $ 40 billion in market value.

Clinton went on to reiterate her position that drug price hikes should be linked with better patient outcomes and demonstrated improvements in value, and demanded that Mylan «immediately reduce the price of EpiPens.»

And it's already in the hot seat over its drug price hikes, so it can't raise prices much further without risking another scandal.

He pointed out, too, that the rate of drug price hikes has been declining in recent quarters — an indication, he said, that even without political action, «the pricing environment today is already dramatically different from what it was in 2013 to 2015.»